| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab169276-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
| Ab169276-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $267.90 | |
| Ab169276-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $657.90 | |
| Ab169276-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $957.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Brodalumab (anti-IL17RA) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-17Ra / CD217, >95%, high purity, Human IgG2 |
|---|---|
| Synonyms | Recombinant Brodalumab Antibody | Brodalumab | AMG 827 | KHK4827 | Brodalumab (anti-IL17RA) | Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) | CANDF5 antibody | CD217 antibody | CD217 antigen antibody | CDw217 antibody | CTLA8 antibody | HIL 17R ant |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | IL-17Ra / CD217 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | Antibody of Interleukin 17 receptor A |
| Product Description | Brodalumab is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG2 |
| Light Chain Type | kappa |
| SDS-PAGE | 144.06 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1174395-19-7 |
Brodalumab (anti-IL17RA) (Ab169276) - Flow Cytometry
Flow Cytometry analysis of K562 cells labelling IL17RA (red) with Brodalumab (anti-IL17RA) (Ab169276) . Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG2. Black - Unlabelled control, cells without incubation with primary antibody.
Brodalumab (anti-IL17RA) (Ab169276) - SEC
The purity of Brodalumab (anti-IL17RA) (Ab169276) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 376 |
|---|---|
| Wikipedia | Brodalumab |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0707874 | Certificate of Analysis | Jul 05, 2024 | Ab169276 |
| ZJ23F0901155 | Certificate of Analysis | Sep 28, 2023 | Ab169276 |
| ZJ23F0901154 | Certificate of Analysis | Sep 28, 2023 | Ab169276 |
| 1. Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T et al.. (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.. J Allergy Clin Immunol, 130 (1): (145-54.e9). [PMID:22677045] [10.1021/op500134e] |
| 2. Girolomoni G, Mrowietz U, Paul C. (2012) Psoriasis: rationale for targeting interleukin-17.. Br J Dermatol, 167 (4): (717-24). [PMID:22716185] [10.1021/op500134e] |
| 3. Russell CB, Rand H, Bigler J, Kerkof K, Timour M, Bautista E, Krueger JG, Salinger DH, Welcher AA, Martin DA. (2014) Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.. J Immunol, 192 (8): (3828-36). [PMID:24646743] [10.1021/op500134e] |
| 4. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A. (2014) Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis.. N Engl J Med, 370 (24): (2295-2306). [PMID:24918373] [10.1021/op500134e] |
| 5. Chiricozzi A. (2014) Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.. Actas Dermosifiliogr, 105 Suppl 1 (13): (9-20). [PMID:25398488] [10.1021/op500134e] |
| 6. Mullard A. (2017) New plaque psoriasis approval carries suicide warning.. Nat Rev Drug Discov, 16 (3): (155). [PMID:28248935] [10.1021/op500134e] |
